Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Current Assets: 2019-2025

Historic Current Assets for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $277.6 million.

  • Pharming Group N.V's Current Assets fell 1.63% to $277.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.6 million, marking a year-over-year decrease of 1.63%. This contributed to the annual value of $278.4 million for FY2024, which is 11.98% down from last year.
  • Latest data reveals that Pharming Group N.V reported Current Assets of $277.6 million as of Q3 2025, which was up 12.95% from $245.8 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Current Assets registered a high of $316.3 million during Q4 2023, and its lowest value of $252,048 during Q3 2022.
  • Its 3-year average for Current Assets is $274.4 million, with a median of $278.4 million in 2024.
  • Per our database at Business Quant, Pharming Group N.V's Current Assets tumbled by 99.90% in 2022 and then surged by 115,646.60% in 2023.
  • Pharming Group N.V's Current Assets (Quarterly) stood at $249.4 million in 2021, then increased by 11.25% to $277.5 million in 2022, then grew by 14.00% to $316.3 million in 2023, then dropped by 11.98% to $278.4 million in 2024, then decreased by 1.63% to $277.6 million in 2025.
  • Its last three reported values are $277.6 million in Q3 2025, $245.8 million for Q2 2025, and $214.1 million during Q1 2025.